Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.
You may also be interested in...
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.
Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
Biosimilars major Celltrion has announced further progress on its biosimilar Xolair candidate, as it faces off against the likes of Glenmark to introduce global competition to Genentech/Novartis’ blockbuster cardiovascular biologic.